Key result
Pharmacologic prophylaxis strategies for venous thromboembolism after joint arthroplasty vary widely across clinical practice guidelines due to limitations in available evidence.
Answers are grounded in this paper and cite their sources.
Different clinical practice guidelines recommend varying strategies for VTE prophylaxis after joint arthroplasty, reflecting a trade-off between preventing thrombosis and avoiding bleeding.
Total hip and total knee replacement procedures offer the potential to relieve pain and disability, but both surgeries expose patients to a substantial risk of venous thromboembolism. Most experts agree that postoperative pharmacologic prophylaxis is warranted, but different clinical practice guidelines encompass a relatively wide spectrum of strategies. Recommended approaches range from low-dose aspirin monotherapy at one extreme to the long-term use of an anticoagulant such as low-molecular-weight heparin at the other. These differences are partly explained by limitations of the available evidence and partly attributable to the degree to which different physicians prioritize the avoidance of bleeding versus the . . .
No takes yet. Share an insight, caveat, or question.
David García (2018) conducted an editorial in Venous thromboembolism after joint arthroplasty. Pharmacologic prophylaxis was evaluated. Pharmacologic prophylaxis strategies for venous thromboembolism after joint arthroplasty vary widely across clinical practice guidelines due to limitations in available evidence.
Synapse has enriched 10 related papers. Consider them for comparative context: